About the JDRF T1D Fund
Accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic commercial investments.
Why we founded the T1D Fund
There is no other fund like us
In 2015, JDRF identified a lack of investment in the T1D market. This was causing a gap between scientific advancements and commercial solutions made available to those who need them.
So JDRF created the T1D Fund to accelerate growth in the T1D investment market.
As a separate company, we can make compelling investments to stimulate private capital financing, whilst remaining efficient and nimble.
in the United States
meet target A1c
will have T1D by 2050
of which T1D is a part
The JDRF T1D Fund
A philanthropic vehicle run as a venture capital fund.
Our aim is to create a new investment market aimed at delivering solutions to those living with or at risk of developing T1D.
Launched in December 2016, the T1D Fund is a combination of venture capital and philanthropy focused solely on T1D.
It’s the first scale, mission-driven venture philanthropy fund focused on commercial investments in companies developing life-saving T1D products.
The portfolio consists of therapeutics, devices, vaccines, and diagnostics. We have already have made several investments and the list will only continue to grow.
The relationship between JDRF and the T1D Fund
The T1D Fund is JDRF’s front door to all T1D commercial opportunities.
With JDRF as our parent company, we’re in an unparalleled position: we benefit from JDRF’s expertise and knowledge as the largest global funder of T1D research.
However, JDRF and the T1D Fund are two separate entities, run by separate teams, following separate governance, and each with a different approach to opportunities.